The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Gallbladder Cancer: expert consensus statement
Open accessAbstract
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists was convened on 15 January 2014 to review current evidence on the management of gallbladder carcinoma in order to establish practice guidelines. In summary, within high incidence areas, the assessment of routine gallbladder specimens should include the microscopic evaluation of a minimum of three sections and the cystic duct margin; specimens with dysplasia or proven cancer should be extensively sampled. Provided the patient is medically fit for surgery, data support the resection of all gallbladder polyps of >1.0 cm in diameter and those with imaging evidence of vascular stalks. The minimum staging evaluation of patients with suspected or proven gallbladder cancer includes contrasted cross-sectional imaging and diagnostic laparoscopy. Adequate lymphadenectomy includes assessment of any suspicious regional nodes, evaluation of the aortocaval nodal basin, and a goal recovery of at least six nodes. Patients with confirmed metastases to N2 nodal stations do not benefit from radical resection and should receive systemic and/or palliative treatments. Primary resection of patients with early T-stage (T1b-2) disease should include en bloc resection of adjacent liver parenchyma. Patients with T1b, T2 or T3 disease that is incidentally identified in a cholecystectomy specimen should undergo re-resection unless this is contraindicated by advanced disease or poor performance status. Re-resection should include complete portal lymphadenectomy and bile duct resection only when needed to achieve a negative margin (R0) resection. Patients with preoperatively staged T3 or T4 N1 disease should be considered for clinical trials of neoadjuvant chemotherapy. Following R0 resection of T2-4 disease in N1 gallbladder cancer, patients should be considered for adjuvant systemic chemotherapy and/or chemoradiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684
Self-citationStudy Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Gallbladder cancer: lessons from a rare tumour
Wistuba, I. I., & Gazdar, A. F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1429 · Cited by 454
Baxi, R., Sharma, M., Roseby, R., Polnay, A., Priest, N., Waters, E., Spencer, N., & Webster, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001746.pub3 · Cited by 332
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3579 · Cited by 318
Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial
Knox, J. J., Hedley, D. W., Oza, A. M., Feld, R., Siu, L. L., Chen, E. X., Nematollahi, M., Pond, G. R., Zhang, J., & Moore, M. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.51.008 · Cited by 305
Corvera, C. U., Blumgart, L. H., Akhurst, T., DeMatteo, R. P., D’Angelica, M., Fong, Y., & Jarnagin, W. R. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.07.002 · Cited by 292
Self-citationZatonski, W. A., Przewozniak, K., Lowenfels, A. B., Boyle, P., Maisonneuve, P., Bueno de Mesquita, H. B., Moerman, C. J., Ghadirian, P., Simard, A., Jain, M., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1132 · Cited by 286
Cited by
Roa, J. C., García, P., Kapoor, V. K., Maithel, S. K., Javle, M., & Koshiol, J. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00398-y · Cited by 401
Self-citationAgarwala, V., Ramaswamy, A., Dsouza, S., Pande, N., Goel, M., Patkar, S., & Ostwal, V. (2018) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-018-0809-8 · Cited by 6
Metadata
- Authors
- Aloia, T. A., Járufe, N., Javle, M., Maithel, S. K., Roa, J. C., Adsay, V., Coimbra, F. J. F., & Jarnagin, W. R.
- Venue
- HPB
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 17
- Issue
- 8
- Pages
- 681-690
- ISSN
- 1365-182X (ISSN-L)
- OpenAlex
- W1480537273
- Cited by
- 472
- References
- 25
- FWCI
- 23.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gallbladder Cancer: expert consensus statement. https://app.cochat.ai/papers/10.1111/hpb.12444
- The paper
- Aloia, T. A., Járufe, N., Javle, M., Maithel, S. K., Roa, J. C., Adsay, V., Coimbra, F. J. F., & Jarnagin, W. R. (2015). Gallbladder Cancer: expert consensus statement. HPB. https://doi.org/10.1111/hpb.12444
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
